Objectives-To investigate whether persistent enhancement detected on contrastenhanced sonography at postoperative day 1 (early contrast-enhanced sonography) after cryoablation of renal tumors implies the presence of residual viable tumor tissue, defined as residual enhancing tissue on reference imaging (computed tomography or magnetic resonance imaging) performed 6 months after the procedure.
T he widespread use of cross-sectional imaging has increased the incidental detection of relatively small, asymptomatic renal tumors. Nephron-sparing surgical procedures are considered the standards of care for these tumors. In the elderly and in comorbid patients with limited life expectancy, however, active surveillance and ablation can be offered. Cryoablation, in particular, has become increasingly accepted in clinical practice.
Imaging has a crucial role in evaluating the technical success of renal cryoablation. In several institutions, after the procedure, the patient undergoes a 24-hour overnight observation with a complete blood count. The first imaging examination is performed before patient discharge on postoperative day 1 to document technical success, to assess for development of early complications after final computed tomography (CT) performed at the end of the procedure, and to provide a baseline for subsequent imaging. If no relevant findings are seen, postablation imaging is then performed at increasing follow-up intervals, typically 6 and 12 months after ablation and yearly thereafter.
Postablation imaging is usually performed with CT or magnetic resonance imaging (MRI). Contrastenhanced sonography is becoming a good alternative, 1 especially to examine the patient on day 1, as information on technical success and the presence of complications can be obtained by urologists themselves without radiation and the use of nephrotoxic contrast agents. The hallmark of successful tumor ablation is lack of intralesional enhancement. A perilesional rim of enhancing tissue is often present, which likely represents reactive changes, not residual tumor tissue. [2] [3] [4] [5] [6] [7] Intralesional enhancement should raise concern for an incompletely treated tumor. For cryoablation, however, there is increasing evidence that tumor enhancement can also persist for some time in completely ablated lesions. A previous study reported enhancement on MRI on postoperative day 1 in 35% of patients with successfully treated tumors, 8 and according to a recent prospective investigation, persistent intralesional enhancement was shown on MRI 2 to 3 days after cryoablation in up to 60% of successfully treated lesions. 9 Other studies reported persistent enhancement lasting up to several months after the procedure on both CT [10] [11] [12] and MRI. 8 To the best of our knowledge no study dealt with the early appearance on contrast-enhanced sonography of tumors treated with cryoablation. The aim of this study was to investigate whether persistent tumor enhancement on contrast-enhanced sonography on postoperative day 1 after cryoablation implies tumor viability, which is identified as residual enhancing tissue on reference imaging (CT or MRI) performed 6 months after the ablation procedure.
Materials and Methods
Our Institutional Review Board approved this retrospective study, and data were processed without any patientidentifying information. Hence, the requirement for informed consent was waived.
A computer search of the databases at our institutions was done for the clinical and radiologic records of the patients who underwent percutaneous CT-guided cryoablation of renal tumors from November 2011 to August 2015.
Patients who had contrast-enhanced sonograms and digital clips available for review that were obtained in the postoperative day 1 (early contrast-enhanced sonography) and CT or MRI scanning performed 6 months or more after the procedure were included, whereas patients lacking early contrast-enhanced sonographic investigations and those lost to follow-up were excluded. The median length of follow-up was 26 months (range, 6-54 months).
Four patients died of comorbid medical conditions after follow-ups ranging from 7 to 23 months. No patient in our study died of disease progression of the ablated tumors.
The final population under study was 74 patients with early contrast-enhanced sonographic investigations. Four patients had multiple renal masses in the same kidney, for which 1 (n 5 2) or 2 (n 5 2) ablation procedures were scheduled. Five patients had only 1 kidney. Three more patients had previous nephron-sparing surgery for renal cancer. In patients with ablation of Siemens AG (Berlin, Germany).
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Cryoablation
Interventional radiologists with at least 5 years of experience performed the procedures. Tumor biopsy was performed before placement of cryoprobes using an 18-gauge core biopsy system. In patients with multiple tumors, only the largest was biopsied. All treatments were performed with a Seednet Gold cryoablation system (Galil Medical, Yokneam, Israel) with the patient prone or oblique in the CT scanner under conscious sedation. Probes were chosen to achieve optimal coverage of the tumor by the ice ball.
Once the probes were inserted into the tumor, cryoablation was performed with a double freeze-thaw cycle (10-minute freezing cycle separated by a 10-minute passive thawing cycle). During freezing, repeated control ablations with sequential CT acquisitions were performed to monitor ice ball expansion, and to rule out any damage to surrounding vulnerable organs. At the end of the procedure, active thawing of the cryoprobes with helium allowed their rapid removal, followed by a final CT acquisition to identify major complications, which were defined as those that might have resulted in any change in patient treatment or deviation from the regular follow-up protocol. Primary technical success was considered achieved if a complete freeze-thaw-freeze cycle was applied with extension of the ice ball 5 mm beyond the tumor margins.
Follow-up Imaging
Contrast-enhanced sonography was performed by abdominal radiologists who had at least 5 years of experience in imaging of the kidney with microbubble contrast agents. Contrast-enhanced sonographic investigations were performed on postoperative day 1 with different ultrasound equipment and contrast-specific nondestructive modes (Table 1) . A 1.2-to 2.4-mL bolus of sulfur hexafluoride-filled microbubbles (SonoVue; Bracco SpA, Milan, Italy) was injected by using a 20-gauge cannula, followed by a 10-mL normal saline flush. The transducer was moved during the contrast agent circulation to explore all lesion aspects, and video clips were recorded and stored in real time. The presence of clinically important complications was noted. In patients who had residual lesion vascularity on postoperative day 1 contrast-enhanced sonography, the study was repeated 1 month after the treatment.
Computed tomography or MRI performed 6 months after cryoablation was considered the reference procedure for assessing the absence of or residual disease. The criterion for successful treatment was replacement of the tumor with scar tissue without evidence of growth or enhancement. Treatment failure was considered the presence of a growing lesion, any type of intralesional enhancement on CT or MRI performed 6 months after the treatment, or both. 3, 4 Magnetic resonance imaging was performed in 55 of 74 patients (74%), whereas CT was used in the remaining 19 (26%). Multiparametric MRI was performed on a 1.5-T system (Achieva; Philips Healthcare, Eindhoven, the Netherlands). The following sequences were obtained: coronal and axial T2-weighted images; axial in-phase and out-of-phase spoiled gradient echo images; axial T1-weighted images with and without fat suppression; and axial 3D fat-suppressed T1-weighted gradient echo sequences (eTHRIVE) obtained before and 30, 90, and 180 seconds after gadolinium contrast agent administration. Subtraction of precontrast and postcontrast images was performed in all cases.
Computed tomography was performed with a variety of multidetector-row CT scanners. Both nonenhanced and contrast-enhanced CT images in the arterial and nephrographic phases were obtained (30 and 90-100 seconds after the injection of contrast material, respectively).
Further follow-up imaging with CT or MRI was scheduled 12, 18, 24, and 36 months after cryoablation. The results of these investigations were not considered for the purpose of this study.
Image Analysis
Two independent sonologists (M.B. and C.C.) were asked to evaluate the early contrast-enhanced sonograms in random order and, for the patients who had residual lesion vascularity on early contrast-enhanced sonography, also those obtained after 1 month. The readers were blinded to the findings of the reference procedures and were unaware of the timing of the contrast-enhanced sonographic investigations. Any identifying information was masked. The readers had 20 and 10 years of experience in urologic imaging and 17 and 6 years of experience in renal contrast-enhanced sonography, respectively. They were asked to score intralesional vascularization in 4 groups: no intralesional enhancement, only a few intralesional vessels, focal areas of intralesional enhancement, and diffuse intralesional enhancement. Perilesional rim of enhancement (ie, enhancement of the ablation bed outside the tumor margins) was excluded from the evaluation. Magnetic resonance and CT images obtained 6 months after the ablation were reviewed in random order by a radiologist (F.S.) with 27 years of experience in renal imaging. The reviewer compared the MRI and CT scans obtained before and 6 months after cryoablation, assessing lesion size and contrast enhancement changes. According to previous investigations, ablation was considered successful if there was complete absence of enhancement and the lesion was stable or decreased in size. Intralesional enhancement was regarded as a sign of residual tumor disease. 7 
Statistical Analysis
Inter-reader agreement in evaluating residual lesion enhancement on early contrast-enhanced sonography was assessed with weighted j statistics using commercially available software (MedCalc for Windows, version 12.7.7.0; MedCalc Software, Mariakerke, Belgium). Agreement was graded as poor (j < 0.20), moderate (j 5 0.20-0.40), fair (j 5 0.40-0.60), good (j 5 0.60-0.80). and very good (j 5 0.80-1.00). Comparison of persistent enhancement rates on early contrast-enhanced sonography in successfully treated lesions for clear cell renal cell carcinoma, papillary renal cell carcinoma, and oncocytoma was performed by a v 2 test. A statistically significant difference was denoted by P < .05.
Results
The 74 patients in the study included 55 men and 19 women with a mean age 6 SD of 71 6 9 years (median, 72 years; range, 52-89 years). The mean size of the renal masses was 2.3 6 0.9 cm (range, 0.6-5.0 cm).
Histologic confirmation was available for 65 of 74 patients (88%) patients: 12 of 74 lesions (16%) were benign, and 53 (72%) were malignant. In the remaining 9 patients (12%), biopsy was nondiagnostic (Table 2) . After the ablation procedures, 3 patients had fever; 3 developed perirenal hematomas; and 1 had pneumothorax. Discharge was delayed 1 to 3 days in these patients, but no other deviation from the regular management protocol was necessary.
Inter-reader agreement in assessing intratumoral vascularization during the early contrast-enhanced sonographic investigations was very good (j 5 0.90). Both readers considered the ablated lesions avascular in 33 of 74 cases, with minimum persistent enhancement in 21 cases, focal intralesional enhancement in 5, and heavy enhancement in 8 cases. In 7 patients, there were differences. Reader 1 considered 6 lesions avascular, which were considered to have minimum enhancement by reader 2, and 1 lesion to have minimum enhancement, which was considered to have no enhancement by reader 2.
Four lesions that showed focal enhancement on early contrast-enhanced sonography persisted after 1 month (Figure 1) , and 1 lesion that was considered avascular and was not investigated after 1 month had a residual tumor on reference CT performed 6 months after the procedure. Both readers considered this last lesion avascular on early contrast-enhanced sonography by the presence of an area lacking vascularity in the region of the ablated tumor, but CT performed 6 months after the procedure showed that the lesion was still viable, whereas an adjacent area of the parenchyma was ablated.
Ablation was successful in the remaining 69 of 74 patients (93%; Table 3 ). On the early contrast-enhanced sonographic investigations, 32 lesions were considered avascular by both readers (Figure 2 ), and 37 had residual vascularity. Of them, 28 were considered to have a few intralesional vessels by 1 or both readers ( Figure 3) ; 1 had focal enhancement; and 8 had diffuse intralesional enhancement ( Figure 4 ). All of these lesions were avascular on contrast-enhanced sonography performed 1 month after the treatment. In successfully treated lesions, on early contrast-enhanced sonography, no statistically significant differences were found in persistent enhancement rates for clear cell renal cell carcinoma, papillary renal cell carcinoma, and oncocytoma.
Discussion
Given that renal lesions are treated in situ, after cryoablation, a rigorous follow-up protocol is required to assess the outcome of the procedure, which, however, has not been fully standardized. Compared to sonography, CT guidance is preferred for guiding cryoablation because of its ability to accurately monitor the ice ball size and location, which helps predict subsequent cell death and therefore the success of therapy. Also, imaging can be performed on postoperative day 1 to identify clinically relevant complications not identified during the treatment or to monitor the evolution of already recognized complications before discharging the patient. It is also the first occasion to investigate the viability of the tumor. The same criteria used to assess tumor viability after radiofrequency and other heat-based ablation modalities cannot be used when lesions are treated with cryoablation because histologic changes in tissues are different. Heat-based ablation modalities induce coagulative necrosis of the tumor tissue and obliterates feeding vessels. 13, 14 Thus, the zone of necrosis is virtually avascular. Cryoablation causes cell death by 2 sequential and synergistic mechanisms. Intracellular and extracellular ice crystals are directly cytotoxic and lead to destruction of intracellular organelles and cell membranes, whereas vessel thrombosis secondary to microvascular damage can occur over several days. 8, 15, 16 When the frozen tissue is therefore thawed after cryotherapy, persistent flow can be observed in intratumoral vessels. In a study evaluating pig tumors treated with cryoablation, Rupp et al 17 found delayed vascular obliteration and thrombosis, with capillaries affected first and venules affected 2 to 3 days after treatment.
Several studies investigated renal tumors on postoperative day 1 after cryoablation, 2, 4, 5, 8, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] but either the lesion appearance was not described, or the findings were difficult to interpret. Perilesional rim enhancement is often seen on all imaging modalities and occasionally misinterpreted as residual viable tissue at the periphery of the tumor. This appearance is actually a physiologic phenomenon likely due to reactive changes in the normal tissues surrounding the ablation area. Any nodular or diffuse intralesional enhancement is considered a sign of persistent disease. Early persistent enhancement on MRI, however, is a common finding after cryoablation. 8, 9 In a recent prospective study with 30 patients, 9 it was seen in up to 60% of successfully ablated lesions on postoperative days 2 and 3, in 52% at 5 to 7 days, and in only 1 lesion (4%) after 1 month. 9 It is therefore necessary to schedule further investigations in patients with residual tumor vascularity on early contrast-enhanced sonography after cryoablation, as persistent enhancement in successfully treated tumors fades with time, whereas in residual tumors, it is sustained for 1 month or more.
Previous investigations reported no cases of intralesional enhancement in successfully ablated tumors on contrast-enhanced sonography either after cryoablation or with other modalities. 7, [28] [29] [30] [31] [32] [33] [34] Our study shows that this pattern is common on contrast-enhanced sonography as well, as it was identified in 37 of 69 successfully ablated tumors (53%). In our study, all of these lesions were avascular after 1 month. Although diffuse intralesional enhancement on postoperative day 1 is relatively common in successfully ablated tumors, accounting for up to 11% of patients (8 of 69) in our study, focal intralesional enhancement should raise concern for persistent disease, as in our study, only 1 of 5 lesions with this pattern was successfully ablated on the reference procedure. Similar results were found with MRI. Using MRI, a previous investigation showed statistically significantly higher early persistent vascularization for clear cell renal cell carcinoma compared with other renal cell carcinoma subtypes. 9 In our study, early persistent vascularity was not correlated with the histologic characteristics of the lesions. A possible explanation relies on the very high sensitivity of contrast-enhanced sonography for depiction of minimum intralesional flow. Contrast-enhanced sonography is more sensitive than CT in detecting blood flow in hypovascular lesions. 35 Although no previous investigation compared contrastenhanced sonography and MRI for this purpose, we can speculate that contrast-enhanced sonography might be able to show subtle residual vascularity in hypovascular tumors after cryoablation that is not detectable on MRI. Further studies comparing contrast-enhanced sonography and MRI in the same series of patients early after cryoablation are necessary to clarify this point.
Our work had some limitations, with the principal one being its retrospective nature. Changes in enhancement characteristics over time in tumors that are still vascularized on early contrast-enhanced sonography were not systematically investigated, since imaging was performed for clinical reasons only. Another limitation was the relatively high number of nondiagnostic biopsies (12%). Finally, confirmation of residual tumors was based on imaging criteria only. Biopsy was not repeated in patients with residual tumors on CT or MRI performed 6 months after the procedures, which was considered the reference imaging procedure.
In conclusion, evaluation of the therapeutic response after cryoablation is conducted by imaging studies, and contrast-enhanced sonography is increasingly used on postoperative day 1 to look for complications before patient discharge. Any persistent enhancement should raise concern for an incompletely ablated tumor. Intratumoral enhancement on postoperative day 1, however, does not imply viable tumor persistence. Repeated contrast-enhanced sonography after 1 month is recommended in lesions that maintain vascularity on postoperative day 1 to differentiate between successful cryoablation and a residual tumor.
